TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, and OviTex LPR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
BörsenkürzelTELA
Name des UnternehmensTELA Bio Inc
IPO-datumNov 08, 2019
CEOMr. Antony Koblish
Anzahl der mitarbeiter209
WertpapierartOrdinary Share
GeschäftsjahresendeNov 08
Addresse1 Great Valley Parkway, Suite 24
StadtMALVERN
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl19355
Telefon14843202930
Websitehttps://www.telabio.com/
BörsenkürzelTELA
IPO-datumNov 08, 2019
CEOMr. Antony Koblish
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten